SCHEMBL7388809

SCHEMBL7388809

CCOCCc1ccc(C)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 6/20 0.53
CYP1A2 P05177 2/20 0.48
CYP2A6 P11509 1/20 0.48
TAAR1 Q96RJ0 1/20 0.48
AGXT P21549 2/20 0.41
IDO1 P14902 1/20 0.41
PKM P14618 1/20 0.40
HRH3 Q9Y5N1 1/20 0.39
DRD2 P14416 1/20 0.39
DRD4 P21917 1/20 0.39
DRD3 P35462 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
RECQL P46063 1/20 0.39
IGF1R P08069 1/20 0.38
ALOX15 P16050 1/20 0.38
DAO P14920 1/20 0.38
MAPT P10636 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24603048 0.96 KCNH2 (0.51) KCNH2CYP1A2CYP2A6TAAR1AGXT
SCHEMBL1338721 0.91 KCNH2 (0.41) KCNH2TAAR1
SCHEMBL21899558 0.90 KCNH2 (0.49) KCNH2CYP1A2CYP2A6TAAR1AGXT
SCHEMBL22007381 0.89 KCNH2 (0.53) KCNH2CYP1A2CYP2A6TAAR1AGXT
SCHEMBL9008786 0.88 KCNH2 (0.59) KCNH2CYP1A2CYP2A6TAAR1AGXT
SCHEMBL20234296 0.87 KCNH2 (0.56) KCNH2CYP1A2CYP2A6TAAR1AGXT
SCHEMBL12299452 0.84 KCNH2 (0.53) KCNH2CYP1A2CYP2A6TAAR1AGXT
SCHEMBL12037019 0.84 TAAR1 (0.50) KCNH2CYP2A6TAAR1MAPT
SCHEMBL16151476 0.82 KCNH2 (0.62) KCNH2CYP1A2CYP2A6TAAR1AGXT
SCHEMBL13639151 0.81 KCNH2 (0.58) KCNH2CYP1A2CYP2A6TAAR1DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7226950-B2 Sodium channel modulators THERAVANCE, INC. (US) 2007-06-05 US disclosed
US-6420418-B1 INHIBITION AND PREVENTION OF LEUKOCYTE ADHESION; USED TO TREAT ADHESION-MEDIATED DISEASES SUCH AS ASTHMA, ALLERGIC RHINITIS, MULTIPLE SCLEROSIS; ATHEROSCLEROSIS, AND INFLAMMATORY BOWEL DISEASE MERCK & CO., INC. 2002-07-16 US disclosed
WO-2001012183-A1 HETEROCYCLE AMIDES AS CELL ADHESION INHIBITORS MERCK & CO., INC. (US) 2001-02-22 WO disclosed